Munich - Delayed Quote EUR

Biofrontera Inc. (AI10.MU)

0.7950

0.0000

(0.00%)

At close: October 31 at 3:18:53 PM GMT+1

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024.BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera”

GlobeNewswire 11 days ago

BFRI

BFRIW
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.Biofrontera’s RhodoLED XL and BF-RhodoLED lamps deliver red light energy using long-lasting light-emitting diode (LED) arrays. WOBURN, Mass., Dec

GlobeNewswire 27 days ago

BFRI

BFRIW
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will ...

ACCESS Newswire last month

BFRI

BFRIW
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s asse

GlobeNewswire last month

BFRI

BFRIW
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc (BFRI) reports significant clinical progress and cost reductions, despite weather-related shipment delays impacting Q3 revenue.

GuruFocus.com 2 months ago

BFRIW
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

BFRIW
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to pru

GlobeNewswire 2 months ago

BFRI

BFRIW
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for ...

ACCESS Newswire 2 months ago

BFRI

BFRIW
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing

GlobeNewswire 2 months ago

BFRI

BFRIW
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Rosalind Advisors, Inc. (Trades, Portfolio), a notable investment firm, recently adjusted its investment in Biofrontera Inc (NASDAQ:BFRI), a biopharmaceutical company based in the USA. On September 30, 2024, the firm executed a reduction in its holdings by 8,771 shares, resulting in a new total of 495,490 shares.

GuruFocus.com 2 months ago

BFRIW
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim results expected November 2024.BCC is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and com

GlobeNewswire 3 months ago

BFRI

BFRIW
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Biofrontera Inc (BFRI) reports a 34% revenue increase and significant expense reductions, setting the stage for future profitability.

GuruFocus.com 3 months ago

BFRIW
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA) supported by two Phase 1 safety studiesAK is the second most common diagnosis made by dermatologists in the United States1An estimated 13 million treatments given each year for AK in the US2 WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a bi

GlobeNewswire 3 months ago

BFRI

BFRIW
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare ...

ACCESS Newswire 3 months ago

BFRI

BFRIW
Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biofrontera ( NASDAQ:BFRI ) Second Quarter 2024 Results Key Financial Results Revenue: US$7.84m (up 34% from 2Q 2023...

Simply Wall St. 5 months ago

BFRI

BFRIW
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prio

GlobeNewswire 5 months ago

BFRI

BFRIW
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended ...

ACCESS Newswire 5 months ago

BFRI

BFRIW
When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?

We feel now is a pretty good time to analyse Biofrontera Inc.'s ( NASDAQ:BFRI ) business as it appears the company may...

Simply Wall St. 6 months ago

BFRI

BFRIW
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalpBiofrontera launched the commercial distribution of the RhodoLED XL on June 10, 2024, shipping the first three machines within 1 week of launch WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commerc

GlobeNewswire 6 months ago

BFRI

BFRIW
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic ...

ACCESS Newswire 8 months ago

BFRI

BFRIW

Performance Overview

Return	AI10.MU	S&P 500
YTD	0.00%	+1.52%
1-Year	-60.64%	+25.82%
3-Year	-98.03%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biofrontera Inc. (AI10.MU)

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Performance Overview